Through bioinformatics analysis, we found that the level of CRABP2 may be related to the response of melanoma to PD-1 and may become a new target to improve the efficacy of immunotherapy by influencing immune infiltration of CAFs. This evidence concerns the gene CRABP2 and melanoma.